[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Cardiology Research UBC\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":160},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,76,105,132],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100631433","observing-the-role-of-inflammation-in-peripheral-artery-disease-and-its-impact-on-heart-and-mobility-health-panacea-o-100631433",false,"NCT07500610","Observing the Role of Inflammation in Peripheral Artery Disease and Its Impact on Heart and Mobility Health: PANACEA-O.","Protocol Title Peripheral Arterial Disease and InflammatioN Study Assessing the Cardiovascular and Functional Effects - Observational Study: PANACEA-O","PANACEA-O","Inclusion Criteria:\n\n* Age \\>\u002F= 19 years of age\n* Ability to provide informed consent before any trial-related activities\n* Symptomatic PAD with intermittent claudication corresponding to Fontaine stage IIa meeting all of the following:\n\n  1. Stable symptoms of PAD with intermittent claudication in Fontaine stage IIa (able to walk without stopping more than 200 m\u002F656 feet\u002F2 blocks) for at least 90 days prior to the day of screening based on patient interview.\n  2. Ankle-brachial-index (ABI) equal to or below 0.90 (the leg with lowest index is chosen in case of bilateral disease) or ≥ 50% stenosis in peripheral artery (excluding carotid) documented by X-ray angiography, MR angiography, CT angiography or Doppler ultrasound, or a history of lower extremity revascularization\n\nExclusion Criteria:\n\n* Current or previous treatment with any immunomodulating agent within 90 days prior to the day of screening.\n* Walking ability limited by conditions other than PAD\n* Planned orthopaedic surgery in the legs, or other major surgery known on the day of screening (surgery affecting walking ability).\n* Vascular revascularisation procedure for PAD of any kind 180 days prior to the day of screening.\n* Planned arterial revascularisation known on the day of screening.\n* Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or transient ischemic attack within 180 days prior to the day of screening.\n* Heart failure presently classified as being in New York Heart Association (NYHA) class III-IV.\n* Signs\u002Fsymptoms of critical limb ischemia (leg gangrene, rest pain, ischemic wounds, etc)","ALL","19 Years",{"count":20,"type":21},50,"ESTIMATED","1 Day","OBSERVATIONAL","This registry aims to collect detailed information about people in Canada who have Peripheral Artery Disease (PAD) and are receiving care in heart clinics while still able to walk and live in the community. Researchers want to better understand what these patients are like at the start of their care and looking at their general health, levels of inflammation in their bodies, and how well they can move and function in daily life.\n\nThe results of this study will help healthcare providers better understand what PAD looks like in today's Canadian heart clinics. It will also help guide future research studies that focus on inflammation and PAD. The researchers believe that PAD patients can be routinely recruited from these clinics, and that most of these patients will have high levels of inflammation (shown by high blood CRP levels) and poor physical ability when they first join. The findings will show that there is a strong need to regularly check for PAD in heart clinics so that patients can be identified early and offered new treatments in the future and especially treatments that may help reduce inflammation.",[26],"Peripheral Vascular Disease",[28,29,30,31,32],"peripheral vascular disease","inflammation","CRP","claudication","ABI","RECRUITING","2026-03-25",{"date":36,"type":37},"2026-03-30","ACTUAL",{"date":39,"type":37},"2025-09-25",{"date":41,"type":21},"2026-07",{"name":43,"class":44},"Cardiology Research UBC","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100621379","spot-analysis-of-natriuresis-to-guide-up--or-down-titration-of-diuretic-therapy-in-ambulatory-patients-with-chronic-heart-failure-100621379","NCT07369856","Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy in Ambulatory Patients With Chronic Heart Failure","Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy in Ambulatory Patients With Chronic Heart Failure (SAND-HF)","SAND-HF","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of heart failure according to the Universal Definition\n* Use of loop diuretics\n* Residing in VCH or PHC regions\n\nGroup-specific inclusion:\n\nGroup 1: Congestion score ≥5 OR objective congestion; stable furosemide ≥1 week Group 2: NYHA I-II; congestion score \\\u003C5; no recent HF hospitalization; stable furosemide ≥1 month Group 3: First 100 eligible patients not meeting criteria for Groups 1 or 2\n\nExclusion Criteria:\n\n* eGFR \\\u003C20 mL\u002Fmin\u002F1.73m²\n* Renal replacement therapy\n* High-risk clinical status requiring hospitalization\n* Inability to consent or perform required urine sampling","18 Years",{"count":56,"type":21},300,"INTERVENTIONAL",[59],"NA","Heart failure is a chronic condition that causes congestion and frequent hospitalizations. Diuretic doses are usually adjusted based on clinical judgment without an objective measure of response. This study will test the feasibility of using point-of-care urine sodium measurements to guide up-titration or down-titration of loop diuretics in ambulatory patients with heart failure.\n\nParticipants will be assigned to one of three groups based on congestion status. Groups 1 and 2 will be randomized 1:1 to natriuresis-guided therapy or standard care. Group 3 will be observational. The 90-day pilot trial will evaluate feasibility, clinical outcomes, and usability of a urine sodium-guided titration strategy.",[62,63],"Heart Failure","Diuretics",[65,66,67],"heart failure","diuretics","management","2026-03-23",{"date":70,"type":37},"2026-03-27",{"date":72,"type":37},"2025-11-04",{"date":74,"type":21},"2027-12-30",{"name":43,"class":44},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":57,"phases":86,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":4},"100545198","robotically-assisted-minimally-invasive-direct-coronary-artery-bypass-with-stenting-randomized-against-coronary-artery-bypass-graft-surgery-100545198","NCT06378775","Robotically-assisted Minimally-invasive Direct Coronary Artery Bypass With Stenting, Randomized Against Coronary Artery Bypass Graft Surgery","Robotically-assisted Minimally-invasive Direct Coronary Artery Bypass With Stenting, Randomized Against Coronary Artery Bypass Graft Surgery: a Pilot Trial","ROBOT RCT","Inclusion Criteria:\n\n1. Multi-vessel CAD with an indication for revascularization,\n2. Presence of at least 1 risk factor for increased risk of post-operative death or major complication,\n\n   * Any patient Age \\> 80, OR\n   * Any patient with eGFR (Glomerular Filtration Rate) \\\u003C 50, OR\n   * Any patient with LVEF \\\u003C 40%, OR\n   * Any patient deemed to be \"frail\" by consulting surgeon. OR\n   * Patients \\> 75 years of age with at least one of the following:\n\n     * Ejection fraction \\\u003C 50%\n     * History of prior CVA (Cerebral Vascular Accident)\n3. Coronary artery anatomy appropriate for a robotically-assisted MIDCAB or regular CABG, vessels other than the left anterior descending with lesions amenable to either CABG or PCI.\n\nExclusion criteria\n\n1. Significant left main coronary artery disease,\n2. Ejection fraction \\\u003C 30%,\n3. Patients with GFR \\\u003C 30,\n4. Patients unable to take dual anti-platelet agents due to high bleeding risk,\n5. Patients requiring emergent surgery, including patients with hemodynamic instability,\n6. Patients with anatomy not suitable for a robotically-assisted approach (by CT chest).",{"count":85,"type":21},80,[59],"The study objective is to compare standard CABG to a hybrid revascularization strategy (RA-MIDCAB + PCI) in patients who have multi-vessel CAD and an indication for surgery, but who have a slightly higher risk of post-operative complications.",[89,90],"Coronary Artery Disease","Multivessel Coronary Artery Disease",[92,93,94,95],"CABG","Hybrid Coronary Revascularization","Robotically-assisted minimally-invasive direct coronary artery bypass","RA-MIDCAB","NOT_YET_RECRUITING","2024-04-21",{"date":99,"type":37},"2024-04-23",{"date":101,"type":21},"2024-05-01",{"date":103,"type":21},"2028-12-01",{"name":43,"class":44},{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":113,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":57,"phases":116,"briefSummary":117,"conditions":118,"keywords":119,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},"100505260","multidisciplinary-approach-for-high-risk-patients-leading-to-early-diagnosis-of-canadians-in-heart-failure-100505260","NCT05859048","Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians in Heart Failure","Multidisciplinary Approach for High Risk Patients Leading to Early Diagnosis of Canadians","MAPLE-CHF","Inclusion Criteria:\n\n* Male or female \\> 40 years of age\n* Informed consent\n* At least two additional risk factors for Heart Failure (HF):\n\n  * Coronary artery disease (either a previous documented type 1 myocardial infarction or coronary artery bypass grafting or percutaneous coronary intervention or documented stenosis or an epicardial coronary artery (50% left main stem or \\>70% left anterior descending, circumflex or right coronary artery)).\n  * Diabetes type 1 or 2.\n  * Persistent or permanent atrial fibrillation.\n  * Previous ischemic or embolic stroke.\n  * Peripheral artery disease (previous surgical or percutaneous revascularization or documented stenosis \\>50% of major peripheral arterial vessel.\n  * Chronic kidney disease (defined as an estimated glomerular filtration rate (eGFR)\\\u003C60 milliliters per minute (mL\u002Fmin)\u002F1.73m2 or eGFR 60-90 mL\u002Fmin\u002F1.73m2 and urine albumin-creatinine ration (UACR) \\>300mg\u002Fg).\n  * Regular loop diuretic use for \\>30 days within 12 months prior to consent.\n  * Chronic obstructive pulmonary disease (COPD) evidenced by one of the following: Pulmonary Function Test (PFT) showing airway obstruction, diagnosis of respiratory physician, CT scan reporting presence of emphysema, or treatment with national guidance advocated COPD therapy.\n\nExclusion Criteria:\n\n* Inability to give informed consent (e.g. due to significant cognitive impairment).\n* Previous diagnosis of heart failure. This is any diagnosis of heart failure with any ejection fraction of any cause.\n* Renal replacement therapy.\n* Anyone who, in the investigator's opinion, is not suitable to participate in the trial for other reasons e.g., a diagnosis which may compromise survival over the study period.","40 Years",{"count":115,"type":21},1360,[59],"The goal of this study is improve the screening of heart failure and identify patients early who are at risk of heart failure.\n\nThe main question\\[s\\] it aims to answer are:\n\n• will an electronic health records (EHR) case finding algorithm for heart failure, followed by N-Terminal pro-brain natriuretic peptide (NT-proBNP) screening and artificial intelligence (AI) echocardiogram compared to usual care identify patients at risk for heart failure earlier than standard of care?\n\nParticipants will be enrolled and randomized to either standard of care (SOC) or intervention arm:\n\nSOC arm: electronic health records will be reviewed over six months for assessments performed to identify heart failure.\n\nIntervention arm: blood sample for N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) at local laboratory . For elevated NT-proBNP results (\\>125pg\u002Fml) an artificial intelligence (AI) echocardiogram and 12 lead electrocardiogram (ECG) will be performed at study site (within 28 days of NT-proBNP result). EHR will be reviewed at six months",[62],[120,121,122],"Heart failure screening","natriuretic peptides","artificial intelligence echocardiography","2024-03-05",{"date":125,"type":37},"2024-03-07",{"date":127,"type":21},"2024-03-01",{"date":129,"type":21},"2029-01-01",{"name":43,"class":44},3,{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":141,"conditions":142,"keywords":146,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":45},"100432072","canadian-scad-study-100432072","NCT04906356","Canadian SCAD Study","Canadian Spontaneous Coronary Artery Dissection (SCAD) Study and Genetic Sub-study (Prospective, Observational Registry With 10 Year Follow-up)","Inclusion Criteria:\n\n1. Patients admitted with ACS (STEMI, NSTEMI or unstable angina)\n2. Documented SCAD on a coronary angiogram (including diagnosis with OCT or IVUS)\n\nExclusion Criteria:\n\n1\\. Patients where SCAD is attributed to atherosclerotic coronary artery disease, with atherosclerotic coronary artery disease stenosis ≥50%",{"count":140,"type":21},3000,"Natural history multicenter, prospective, observational registry with 10-year follow-up",[143,144,145],"Spontaneous Coronary Artery Dissection","SCAD","Fibromuscular Dysplasia",[147,148,149,150,151,144,143],"Fibromuscular displasia (FMD)","Myocardial Infarction","Myocardial Infarction in women","Non-atherosclerotic coronary artery disease (NACAD)","Myocardial Infarction with no obstructive coronary artery disease (MINOCA)","2021-05-25",{"date":154,"type":37},"2021-05-28",{"date":156,"type":37},"2018-12-01",{"date":158,"type":21},"2033-12-01",{"name":43,"class":44},""]